Inovio Pharmaceuticals Inc Stock Nyse
Equities
US45773H1023
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 604K 826K | Sales 2025 * | 8.03M 10.98M | Capitalization | 276M 377M |
---|---|---|---|---|---|
Net income 2024 * | -99M -135M | Net income 2025 * | -93M -127M | EV / Sales 2024 * | 457 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 34.3 x |
P/E ratio 2024 * |
-2.76
x | P/E ratio 2025 * |
-3.53
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Inovio Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 19-03-24 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 02-05-31 |
Chief Tech/Sci/R&D Officer | - | 07-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 03-11-30 |
Lota Zoth
BRD | Director/Board Member | 64 | 17-12-31 |
Jay Shepard
BRD | Director/Board Member | 65 | 20-01-14 |
1st Jan change | Capi. | |
---|---|---|
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |